Keros Therapeutics (KROS) Equity Average (2019 - 2025)
Keros Therapeutics (KROS) has disclosed Equity Average for 7 consecutive years, with $503.4 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Equity Average fell 8.84% year-over-year to $503.4 million, compared with a TTM value of $503.4 million through Dec 2025, down 8.84%, and an annual FY2025 reading of $437.3 million, down 3.22% over the prior year.
- Equity Average was $503.4 million for Q4 2025 at Keros Therapeutics, down from $705.2 million in the prior quarter.
- Across five years, Equity Average topped out at $717.8 million in Q2 2025 and bottomed at $217.4 million in Q2 2022.
- Average Equity Average over 5 years is $380.4 million, with a median of $315.1 million recorded in 2023.
- The sharpest move saw Equity Average surged 1251.11% in 2021, then fell 10.19% in 2022.
- Year by year, Equity Average stood at $230.8 million in 2021, then rose by 12.3% to $259.2 million in 2022, then rose by 21.14% to $314.0 million in 2023, then surged by 75.84% to $552.2 million in 2024, then decreased by 8.84% to $503.4 million in 2025.
- Business Quant data shows Equity Average for KROS at $503.4 million in Q4 2025, $705.2 million in Q3 2025, and $717.8 million in Q2 2025.